Study of NTB-928 for recurrent ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug called NTB-928 for people with ovarian cancer that has come back or stopped responding to treatment. The goal is to see if the drug can help when standard treatments are no longer working well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a confirmed type of ovarian cancer (such as high-grade serous, endometrioid, low-grade serous, clear cell, or carcinosarcoma). Mucinous carcinoma is not eligible.
- Your ovarian cancer has returned or is resistant to treatment, and you have already tried standard treatments that help.
- You agree to use effective birth control during the study and for a period after the last dose if you are of childbearing age.
- You have not taken other experimental drugs or certain cancer treatments shortly before starting this study.
- You are not pregnant or breastfeeding and do not have another active cancer that could interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral drug called NMS-03305293 for women with recurrent ovarian cancer. It may work by targeting a specific protein involved in cancer growth. You may be eligible if you have high-grade serous ovarian cancer, have had limited prior treatments, and do not have a BRCA mutation.
This trial studies whether a targeted treatment, chosen based on tumor biology, can help people with recurrent ovarian cancer. You may be asked to give a tumor biopsy so researchers can analyze specific “signal” activity in your cancer.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This Phase 1 trial tests different doses of two study drugs (M1774 and ZEN-3694) for recurrent ovarian cancer and some recurrent endometrial cancers. It aims to find a safe dose and see how well the treatment works, especially in cancers with certain tumor features.
This trial is testing a new drug, LBL-024, combined with chemotherapy (with or without a targeted therapy called bevacizumab) for ovarian cancer that has stopped responding to standard platinum-based treatment. The goal is to see if this combination can effectively shrink tumors and slow the disease's progression.
This trial tests a new combination therapy (SYS6041 plus another drug) for women with recurrent ovarian cancer. It is for those whose cancer has come back after platinum chemotherapy, and who have not had too many previous treatments. The goal is to see if the combination can shrink tumors or slow disease progression.
Hear when a new Relapsed/Refractory Ovarian Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.